| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Idelalisib |
| Brand | Zydelig® |
| Indication | In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. |
| Assessment Process | |
| Rapid review commissioned | 08/12/2014 |
| Rapid review completed | 30/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 04/06/2015 |
| NCPE assessment completed | 16/02/2016 |
| NCPE assessment outcome | Reimbursement not recommended. |
The HSE has approved reimbursement following confidential price negotiations December 2016.
